# US 2016/0251653 A1 · Therapeutic compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251653 A1
- Document ID: US20160251653A1
- Status: Published application
- Kind: A1
- Application number: 14/864,356
- Filed: 2015-09-24
- Published: 2016-09-01
- Earliest claimed: 2011-02-12
- Assignees: University of Iowa Research Foundation
- Applicants: University of Iowa Foundation
- Inventors: Beverly L. Davidson; Ryan L. Boudreau
- Web page: https://patentgrep.com/patent/US20160251653A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2320/30: Special therapeutic applications
- C12N 2320/53: reducing unwanted side-effects
- C12N 2330/51: Specially adapted vectors
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is directed to RNA interference (RNAi) molecules targeted against a Huntington's disease nucleic acid sequence, and methods of using these RNAi molecules to treat Huntington's disease.

## Claims

### Claim at position 1

1-72. (canceled)

### Claim 73

A nucleic acid encoding an artificial primary miRNA transcript (pri-miRNA) comprising, in order of position, a 5′-flanking region, wherein the 5′-flanking region comprises a 5′-bulge sequence positioned upstream from a 5′-joining sequence; a non-guide region, wherein the 5′-joining sequence is contiguously linked to the non-guide region; a loop region; a guide region; and a 3′-flanking region, wherein the guide region comprises a sequence at least 80% identical to cgaccaugcgagccagca (miHDS.1 guide. SEQ ID NO:7) and the non-guide region is at least 80% complementary to the guide region.

### Claim 74 (depends on 73)

The nucleic acid of claim 73, wherein the guide region consists of 18-30 nucleotides.

### Claim 75 (depends on 73)

The nucleic acid of claim 73, wherein the 5′ joining sequence consists of 5-8 nucleotides.

### Claim 76 (depends on 73)

The nucleic acid of claim 73, wherein the 5′-bulge sequence consists of 1-10 nucleotides.

### Claim 77 (depends on 73)

The nucleic acid of claim 73, wherein the 5′-flanking region further comprises a 5′-spacer sequence positioned upstream from the 5′-bulge sequence.

### Claim 78 (depends on 77)

The nucleic acid of claim 77, wherein the 5′-spacer sequence consists of 10-12 nucleotides.

### Claim 79 (depends on 77)

The nucleic acid of claim 77, further comprising a 5′-upstream sequence positioned upstream from the 5′-spacer sequence.

### Claim 80 (depends on 79)

The nucleic acid of claim 79, wherein the 5′-upstream sequence consists of 30-2000 nucleotides.

### Claim 81 (depends on 73)

The nucleic acid of claim 73, wherein the 3′-flanking region comprises a 3′-joining sequence contiguously linked to the guide region.

### Claim 82 (depends on 81)

The nucleic acid of claim 81, wherein the 3′-joining sequence consists of 5-8 nucleotides.

### Claim 83 (depends on 81)

The nucleic acid of claim 81, wherein the 3′-joining sequence is at least about 85% complementary to the 5′-joining sequence.

### Claim 84 (depends on 81)

The nucleic acid of claim 81, further comprising a 3′-bulge sequence positioned downstream from the 3′-joining sequence.

### Claim 85 (depends on 84)

The nucleic acid of claim 84, wherein the 3′-bulge sequence consists of 1-10 nucleotides.

### Claim 86 (depends on 84)

The nucleic acid of claim 84, further comprising a 3′-spacer sequence positioned downstream from the 3′-bulge sequence.

### Claim 87 (depends on 86)

The nucleic acid of claim 86, wherein the 3′-spacer sequence consists of 10-12 nucleotides.

### Claim 88 (depends on 86)

The nucleic acid of claim 86, further comprising a 3′-downstream sequence positioned downstream from the 3′-spacer sequence.

### Claim 89 (depends on 88)

The nucleic acid of claim 88, wherein the 3′-downstream sequence is about 30-2000 nucleotides in length.

### Claim 90 (depends on 73)

The nucleic acid of claim 73, wherein the loop region is from 15-25 nucleotides in length.

### Claim 91 (depends on 73)

An expression cassette comprising a promoter contiguously linked to the nucleic acid of claim 73.

### Claim 92 (depends on 91)

A vector comprising the expression cassette of claim 91.

### Claim 93 (depends on 90)

The vector of claim 90, wherein the vector is an adeno-associated virus (AAV) vector.

### Claim 94 (depends on 93)

The vector of claim 93, wherein the AAV is AAV1, AAV2, AAV4, AAV5, or AAV2/1.

### Claim 95 (depends on 73)

An isolated microRNA molecule comprising the nucleic acid of claim 73.

### Claim 96 (depends on 73)

A method of inducing RNA interference comprising administering to a subject an effective amount of the nucleic acid of claim 73.

### Claim 97 (depends on 73)

A method of treating a subject with Huntington's Disease, comprising administering to the subject the nucleic acid of claim 73 so as to treat the Huntington's Disease.
